No Data
Shenyang Xingqi Pharmaceutical (300573.SZ): received the pharmaceutical registration certificate for Tafluprost eye drops.
On January 20, Gelonghui reported that Shenyang Xingqi Pharmaceutical (300573.SZ) announced that today, Shenyang Xingqi Pharmaceutical Co., Ltd. received the \"Drug Registration Certificate\" approved and issued by the National Medical Products Administration for Tafluprost Eye Drops. This product is an eye drop solution with Tafluprost as the main ingredient. The Tafluprost Eye Drops approved this time are single-dose products that do not contain preservatives, and their clinical indication is for lowering elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension. Currently, similar generic drugs of Tafluprost Eye Drops have been approved and marketed in China, with the original drug produced by Santen from Japan.
Shenyang Xingqi Pharmaceutical (300573.SZ) has obtained a pharmaceutical registration certificate.
Shenyang Xingqi Pharmaceutical (300573.SZ) announced that the company has received the approval from the National Medical Products Administration for the issuance of Tafluprost...
If EPS Growth Is Important To You, Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Presents An Opportunity
Shenyang Xingqi Pharmaceutical (300573.SZ): The phase I clinical research report for voriconazole eye drops has been obtained.
Shenyang Xingqi Pharmaceutical (300573.SZ) announced that the fluconazole eye drops developed by the company have recently completed the "Evaluation of Fluconazole..."
Shenyang Xingqi Pharmaceutical (300573.SZ): No research, production, or sales of ophthalmic related medical instruments currently.
Gelonghui reported on December 18 that Shenyang Xingqi Pharmaceutical (300573.SZ) stated on the investor interaction platform that the company continues to focus on the ophthalmology field and adheres to a specialized development path, currently not engaged in the research, production, and sales of ophthalmic-related medical instruments. In the future, the company will formulate strategies for industrial extension and collaborative development based on its own development circumstances in conjunction with the company's Global Strategy.
Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Jumps 3.9% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns
Market Participants Recognise Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) Revenues Pushing Shares 26% Higher
